RNA, U6 small nuclear 790, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-790P profile across patient tissues and cancer cell-line models. RNU6-790P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, RNU6-790P is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, RNU6-790P RNA expression shows 7,849 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight CESC, STAD, and UVM as cancer lineages where RNU6-790P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-790P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-790P survival associations across molecular data types. RNU6-790P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-790P RNA expression–survival associations across cancer types. High RNU6-790P expression shows unfavorable associations in CESC, CHOL, UCEC, COAD and UVM, but favorable associations in STAD. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify CESC as the clearest survival context for RNU6-790P RNA expression.
This table summarizes RNU6-790P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-790P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-790P shows lower tumor expression in LUSC and higher tumor expression in STAD and HNSC. The STAD box plot shows higher RNU6-790P RNA expression in tumor versus normal tissue (log2 FC = +1.181, t-test p < 0.001).
This table shows molecular features associated with RNU6-790P in patient tissues and cancer cell lines. In patient samples, RNU6-790P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
